کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5666822 | 1591744 | 2017 | 6 صفحه PDF | دانلود رایگان |

- In vitro activity of ceftaroline against clinical isolates from cancer patients.
- Potent activity against methicillin-susceptible and -resistant staphylococci.
- Active against majority of clinically significant Gram-positive organisms.
- Active against some key Gram-negative bacilli.
- Potential indications in cancer patients include targeted therapy and de-escalation.
Bacterial infections are common in cancer patients. Ceftaroline (CFT) is a broad-spectrum cephalosporin with activity against most Gram-positive organisms (GPOs) and many Gram-negative organisms. In this study, the in vitro activity of CFT was compared with vancomycin (VAN), daptomycin (DAP), linezolid (LZD), trimethoprim/sulphamethoxazole (SXT) and tigecycline (TIG) against bacteria (predominantly blood culture isolates) isolated from cancer patients in 2014 and 2015. CFT was active against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), methicillin-susceptible coagulase-negative staphylococci (MS-CoNS) and methicillin-resistant coagulase-negative staphylococci (MR-CoNS) with MIC90 values (minimum inhibitory concentration that inhibited 90% of the isolates) of 0.25, 2.0, 0.12 and 0.5âmg/L, respectively. MIC90 values for other GPOs were: Bacillus spp., >8.0âmg/L; Corynebacterium spp., 2.0âmg/L; Micrococcus spp., <0.06âmg/L; viridans group streptococci, 0.5âmg/L; Streptococcus pneumoniae, 0.25âmg/L; and Streptococcus spp., <0.06âmg/L. Among the comparator agents, VAN, DAP, TIG and LZD were active against the majority of GPOs tested. CFT also had moderate activity against common extended-spectrum β-lactamase (ESBL)-negative Gram-negative bacilli such as Enterobacter cloacae, Escherichia coli, Klebsiella spp., Proteus mirabilis and Serratia spp.
Journal: International Journal of Antimicrobial Agents - Volume 49, Issue 4, April 2017, Pages 416-421